Clinical trials
Phase 3 Hypertension trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
37 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 3 |
| 2010 | 2 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 6 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 21 |
| Active, not recruiting | 5 |
| Recruiting | 3 |
| Terminated | 3 |
| Unknown status | 3 |
| Enrolling by invitation | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Boehringer Ingelheim | 5 |
| AstraZeneca | 3 |
| Eli Lilly and Company | 3 |
| Novartis | 3 |
| Novartis Pharmaceuticals | 3 |
| GlaxoSmithKline | 2 |
| Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2 |
| Third Military Medical University | 2 |
| United Therapeutics | 2 |
| Alnylam Pharmaceuticals | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hypertension | 37 |
| Cardiovascular Diseases | 5 |
| Essential Hypertension | 4 |
| Hypertension, Pulmonary | 3 |
| Renal Insufficiency, Chronic | 3 |
| Vascular Diseases | 3 |
| Connective Tissue Diseases | 2 |
| Familial Primary Pulmonary Hypertension | 2 |
| Hyperaldosteronism | 2 |
| Lung Diseases | 2 |
Trials
Showing 1 to 25 of 37. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.